Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Entera Bio (NASDAQ:ENTX) reported quarterly losses of $(0.06) per share which met the analyst consensus estimate. This is a 62.5 percent increase over losses of $(0.16) per share from the same period last year. The company reported $57.00 thousand in sales this quarter.
Posted In: ENTX